Cerebrospinal fluid from Alzheimer's disease patients promotes amyloid β-protein oligomerization

Journal of Alzheimer's Disease

Volumn 21, Issue 1, 2010, Pages 81-86

  Ikeda, Tokuhei ^a   Ono, Kenjiro ^a,b   Elashoff, David ^c   Condron, Margaret M ^b   Noguchi Shinohara, Moeko ^a   Yoshita, Mitsuhiro ^a   Teplow, David B ^b   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; amyloid protein; central nervous system; oligomer; oligomerization; photo induced cross linking of unmodified proteins

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; FEMALE; HUMAN; LABORATORY TEST; MALE; OLIGOMERIZATION; PRIORITY JOURNAL; CASE CONTROL STUDY; CHEMISTRY; MENTAL HEALTH; MIDDLE AGED; NONPARAMETRIC TEST;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PEPTIDE FRAGMENTS; STATISTICS, NONPARAMETRIC;

EID: 77954985839     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100075     Document Type: Article

References (19)

1. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430, 631-639.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
3. Wisniewski T, Castano E, Ghiso J, Frangione B (1993) Cere-brospinal fluid inhibits Alzheimer ft-amyloid fibril formation in vitro. Ann Neurol 34, 631-633.
4. [1067] Ono K, Noguchi M, Matsumoto Y, Yanase D, Iwasa K, Naiki H, Yamada M (2005) Cerebrospinal fluid of Alzheimer patients promotes ft-amyloid fibril formation in vitro. Neurobiol Dis 20, 233-240.
5. [1068] Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C (2009) Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284, 4230-4237.
6. Walsh DM, Selkoe DJ (2007) Aft oligomers-a decade of discovery. J Neurochem 101, 1172-1184.
7. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH (2006) A specific amyloid-ft protein assembly in the brain impairs memory. Nature 440, 352-357.
8. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ (2008) Amyloid ft protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci 28, 4231-4237.
9. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepard-son NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-ft protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
10. Fancy DA, Kodadek T (1999) Chemistry for the analysis of protein-protein interactions: rapid and efficient cross-linking triggered by long wavelength light. Proc Natl Acad Sci U S A 96, 6020-6024.
11. Bitan G (2006) Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins. Methods Enzymol 413, 217-236.
12. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB (2003) Amyloid ft-protein (Aft) assembly: Aft40 and Aft42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100, 330-335.
13. Ono K, Condron MM, Teplow DB (2009) Structure-neurotoxicity relationships of amyloid ft-protein oligomers. Proc Natl Acad Sci USA 106, 14745-14750.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services TaskForce on Alzheimer's Disease. Neurology 34, 939-944.
15. Maddalena A, Papassotiropoulos A, Muller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to ft-amyloid peptide. Arch Neurol 60, 1202-1206.
16. Havekes LM, de Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E (1987) A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 28, 455-463.
17. Walsh DM, Lomakin A, Benedek GB, Condron MM, Teplow DB (1997) Amyloid β-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 272, 22364-22372.
18. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomark-er for Alzheimer's disease. Proc Natl Acad Sci USA 102, 2273-2276.
19. Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-linked immunosorbent assay for measuring ft-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66, 190-199.